SCP
IBB icon

Silverleafe Capital Partners’s iShares Biotechnology ETF IBB Stock Holding History

Silverleafe Capital Partners’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-4,997
Closed -$559K – 75
2019
Q1 		$559K Buy
+4,997
New +$548K 0.33% 39

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
N
Natixis Paris, France $28B AUM 26.79% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Silverleafe Capital Partners's IBB Position: Q2 2019 in Review

Silverleafe Capital Partners sold out of iShares Biotechnology ETF (IBB) in Q2 2019, closing a stake of 4,997 shares — an estimated $559K sold.

Silverleafe Capital Partners first reported a position in IBB in Q1 2019 and held it in 1 quarter. The position peaked at $559K in Q1 2019. 646 funds tracked by Wall St. Rank hold IBB as of Q2 2019.

  • Silverleafe Capital Partners reported no remaining iShares Biotechnology ETF position as of Q2 2019 after selling out during the quarter.
  • Silverleafe Capital Partners sold 4,997 iShares Biotechnology ETF shares in Q2 2019, an estimated $559K.
  • Silverleafe Capital Partners first reported a position in iShares Biotechnology ETF in Q1 2019 and held it in 1 quarter.
  • Silverleafe Capital Partners's iShares Biotechnology ETF position peaked at $559K in Q1 2019.
  • 646 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2019.

Based on Silverleafe Capital Partners's 13F filing for Q2 2019, filed 3 Jul 2019.